| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 271.0 | 235.5 | 206.0 |
| Other income | 6.2 | 7.2 | 4.2 |
| Total income | 277.1 | 242.8 | 210.2 |
| Profit before exceptional items & tax | 32.8 | 22.4 | 31.6 |
| Profit before tax | 32.8 | 22.4 | 31.6 |
| Net profit | 24.6 | 16.6 | 23.9 |
| Operating margin | 11.8% | 9.2% | 15.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +2.90% |
|---|---|
| Net profit, quarter on quarter | +48.20% |
| Revenue, year on year | +31.60% |
| Operating profit, year on year | -2.90% |
| Operating profit, quarter on quarter | +75.00% |
BSE results filing, NSE: KRSNAA. Figures extracted from the filing.
Krsnaa Diagnostics Ltd: key numbers
- Share price
- ₹467.60
- Market cap
- ₹1,517 Cr
- Revenue (annual)
- ₹772.8 Cr
- Net profit (annual)
- ₹101.4 Cr
- P/E (TTM)
- 15.6×Sector 52.8×
- Promoter holding
- 27.11%+0.00% QoQ
- FII holding
- 3.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krsnaa Diagnostics Ltd
All →Krsnaa Diagnostics Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 2,710 Mn (+32% YoY) and PAT INR 246 Mn (+3%). EBITDA margin fell to 27% from 29% on Rajasthan fixed costs.
Krsnaa Diagnostics Results Update
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.
Krsnaa Diagnostics Board Meeting Date
Krsnaa Diagnostics intimated that its board will meet on November 2, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. No financial figures are disclosed in this notice.
Krsnaa Diagnostics Partnership
Krsnaa Diagnostics has formed a strategic AI collaboration with AZmed to integrate AI radiology solutions for enhanced operational efficiency and scalable diagnostic reporting.
- From
- AZmed
Krsnaa Diagnostics Other Announcement
Krsnaa Diagnostics Ltd submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.
Krsnaa Diagnostics Convertible Warrants
Krsnaa Diagnostics has allotted 16,21,000 convertible warrants to 2 investors at a price of Rs. 566 per warrant.
- Value
- ₹91.75 Cr